Drug Approval | August 20, 2022
DCGI approves AstraZeneca 's Olaparib film-coated tablets
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
The AICVD tool can predict the risk of cardiovascular disease.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
AstraZeneca also played a critical role in the global response to COVID-19.
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
Subscribe To Our Newsletter & Stay Updated
